- NEWS AND
SANTA ROSA, CA – February 27, 2012 – Osseon® Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex® SB (steerable balloon) in select regions of Europe and Asia. Aesculap is a division of B. Braun Melsungen, a large medical and pharmaceutical company headquartered in Tuttlingen, Germany. The Osseoflex® SB and the other Osseon CE Mark approved VCF medical devices offer a complete platform for treatment of spinal fractures.
“Aesculap is a major medical device company known throughout the world as a quality manufacturer and distributor of surgical instruments. Our new Osseoflex SB (steerable balloon) represents the most precise and controllable treatment device for vertebral compression fracture augmentation currently available to surgeons. Osseon is very excited to partner with Aesculap to distribute our game-changing Osseoplasty® devices and procedures for VCF treatment to patients throughout Europe and the international community and provide state-of-the-art alternatives to the cumbersome devices and procedures currently used to treat fractures of the thoracic and lumbar spine,” said John Stalcup, Ph.D., Osseon’s CEO.
B. Braun is one of the world´s leading healthcare suppliers. Its four divisions orient their products and services toward different medical fields: hospital, surgery, private practice (medical care and doctors´ offices) and extracorporeal blood treatment. Aesculap focuses on products and services for core processes in surgery. Aesculap’s product range includes surgical instruments for open or minimally invasive approaches, implants (e.g., for orthopaedics, neurosurgery and spinal surgery), surgical sutures, sterile container, storage, motor and navigation systems as well as products for cardiology.
Osseon® Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company’s innovative technology and delivery system provides comparable or better efficacy and safety than other commercial solutions, while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients, as well as the physicians and medical facilities that treat them. Its products have received both FDA clearance and the CE Mark for product distribution in the United States and the European Union.
Osseon® is a registered trademark of Osseon Therapeutics, Inc.
For more information, visit our web site at www.osseon.com
CONTACT: Michael Bivens, Director of Business Development, 707.636.5953